Pfizer CEO on Sales, M&A, mRNA, Weight Loss Drug

Bloomberg Television published this video item, entitled “Pfizer CEO on Sales, M&A, mRNA, Weight Loss Drug” – below is their description.

Pfizer Chairman & CEO Albert Bourla discusses earnings, M&A, mRNA outlook, the weight loss drug race, and reducing cost of R&D. He speaks with David Westin on Bloomberg TV’s “Wall Street Week Daily.”

Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com

Connect with us on…

Twitter: https://twitter.com/business

Facebook: https://www.facebook.com/bloombergbusiness/

Instagram: https://www.instagram.com/quicktake/?hl=en

Bloomberg Television YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.


In This Story: Pfizer

Pfizer Inc. (NYSE: PFE) is an American multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

5 Recent Items: Pfizer

BOMBSHELL Vaccine Data + Mystery “TURBO CANCER” Rise In Young People!!

It’s Nearly Here

Happy 2024 or APOCALYPSE? Epstein List, Trump & Jan 6th PLUS Greg Gutfeld – Stay Free #279 PREVIEW

Illumina battles EU regulators over Grail deal

It’s OVER For Pfizer! This Vaccine Lawsuit Could Change EVERYTHING

Leave a Comment

We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.